Take­da takes a swing at RNA small mol­e­cules with dis­cov­ery pact for mul­ti­ple po­ten­tial Evotec pro­grams

Heart­ened by an FDA ap­proval for Roche’s Evrys­di last year as the first small mol­e­cule mod­u­la­tor for RNA, the rest of bio­phar­ma is look­ing to place their bets in the promis­ing field. No stranger to ear­ly-stage dis­cov­ery deals, Take­da has now iced a pact with a Ger­man play­er to chase the first small mol­e­cule lig­and for RNA.

Ger­many-based Evotec will team up with Take­da to dis­cov­er and de­vel­op RNA tar­gets ripe for small mol­e­cule ther­a­peu­tics, the com­pa­ny an­nounced Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.